SA Editor Douglas W. House
Healthcare, Biotech, special situations, event-driven, growth

Can Trovagene Be The Belle Of The Ball?

A little more than a year ago, I wrote my first article on Trovagene (NASDAQ:TROV). I penned it in response to an SA article I read that touted its "billion-dollar" potential. This was an outlandish claim considering TROV's $51M market cap, a thimble's worth of revenue and four employees. Could the market be this inefficient? After perusing the company's amateurish website and reading about the Xenomics flame out, I concluded that the bullish author was either a paid promoter, a long trying desperately to create support for his losing position or a connoisseur of psilocybin mushrooms. There was no evidence that the company would be able to monetize its patents on nucleic acid testing in urine. In my...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details